{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.9","upperLimit":"19.8","value":"17.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from the date of the first dose to the date of death by any cause. It was calculated as (Date of Death minus First dose date plus 1) divided by 30.4375.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Niraparib (300 milligram \\[mg\\], taken as 3 capsules of 100 mg once daily \\[QD\\]) orally beginning on Day 1 of every cycle (28 days) until treatment discontinuation.","id":"OG000","title":"Niraparib 300 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}